"While blockbuster drug innovations have changed health outcomes for decades, we're now seeing signs that GLP-1 medications like Ozempic and Wegovy may be changing something broader: the consumer economy. Originally developed for diabetes and increasingly prescribed for weight loss, these drugs are not just influencing physical health and body size. They're also reshaping collective behavior-how people eat, shop, move, perceive themselves, and make decisions-with significant implications for business leaders."
"Ali Furman is the consumer markets industry leader at PwC and an M&A partner. She writes and speaks widely on consumer markets trends and the future of business. She has been featured in many outlets including ABC, CBS, CNBC, Forbes, Vogue Business, and Bloomberg."
GLP-1 medications originally developed for diabetes are increasingly prescribed for weight loss and are altering health outcomes and social behaviors. These drugs reduce appetite and body size while changing collective behavior around eating, shopping, movement, self-perception, and decision-making. Shifts in consumption patterns and lifestyle choices cascade through the consumer economy, affecting demand for food, retail formats, fitness, and wellness services. Businesses face implications across product development, marketing, retail strategy, and workforce health planning. Companies should anticipate changing preferences and integrate medical-driven behavioral changes into strategic planning to remain competitive.
Read at Harvard Business Review
Unable to calculate read time
Collection
[
|
...
]